EB病毒相关移植后淋巴组织增殖性疾病治疗的研究进展

移植后淋巴增生性疾病(post-transplant lymphoproliferative disorder,PTLD)是实体器官移植和造血干细胞移植术后罕见而致命的并发症。近年来,随着器官移植数量的增加,PTLD发病增加。目前认为PTLD的主要病因是EB(EpsteinBarr)病毒感染。PTLD包含一系列疾病,临床表现不尽相同,一旦确诊,应降低免疫抑制水平,并联合利妥昔单抗、化疗等方案进行治疗。该文旨在总结PTLD治疗方法的进展,为临床上对PTLD患者的管理提供新的思路,从而提高PTLD患者的存活率。

Progress in treatment of Epstein-Barr virus related post-transplant lymphoproliferative disorder

Post-transplant lymphoproliferative disorder (PTLD) is a rare and fatal complication after solid organ transplantation and hematopoietic stem cell transplantation. With the increase in the number of organ transplantation in recent years, the incidence of PTLD has also increased. It is currently believed that the main cause of PTLD is Epstein-Barr virus infection. PTLD contains a series of diseases with different clinical manifestations. Once diagnosed, the level of immunosuppression of patients should be reduced, and treatment with rituximab and chemotherapy should be given. This article aims to summarize the latest progress of PTLD treatment, for the purpose of providing new ideas for clinical management of PTLD patients, and improving the survival rate of PTLD patients.